The strong revenue growth, margin expansion, and raised guidance suggest continued market penetration of MACI. Traders should monitor the commercial manufacturing ramp-up in the new Burlington facility and progress on the UK MHRA application as potential future catalysts.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $37.68entry
- T+1 · 9mo ago −5.31%α −4.86% · $35.68
- T+5 · 9mo ago −9.77%α −8.64% · $34.00
- T+20 · 8mo ago −18.21%α −11.80% · $30.82
- T+60 · 6mo ago −6.71%α −14.46% · $35.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vericel Corp reported strong Q4 and full-year 2025 financial results with total revenue of $276.3 million, driven by 21% growth in MACI revenue. The company achieved a 59% increase in net income to $16.5 million and raised its 2026 revenue guidance to $316-$326 million, signaling continued momentum in its advanced therapies business.
Key Financial Metrics
Key Facts
- Q4 2025 revenue grew 23% YoY to $92.9 million
- Full-year 2025 revenue reached $276.3 million, up 16% from 2024
- MACI revenue grew 21% to $239.5 million for the year
- Net income increased 59% to $16.5 million for the year
- 2026 revenue guidance raised to $316-$326 million
- Record Q4 gross margin of 79% and adjusted EBITDA margin of 40%
Financial Impact
Revenue growth of 16% and net income growth of 59% in 2025 with 2026 revenue guidance suggesting 14-18% growth
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| MACI | $239.5M | +21.0% |
| Burn Care | $36.8M | Not reported |
Risk Factors
- Increased operating expenses due to new facility costs could pressure margins
- Dependence on MACI revenue growth (87% of total revenue)
- Regulatory risks with UK MHRA application
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-012003 |
| Document: vcel-20260226.htm | 0001628280-26-012003 |
| Document: 0001628280-26-012003-index-headers.html | 0001628280-26-012003 |
| Document: 0001628280-26-012003-index.html | 0001628280-26-012003 |
| Document: 0001628280-26-012003.txt | 0001628280-26-012003 |
Track record
30 reports on VCEL
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 1/10 Entry $57.42 Now $57.48 +0.10% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $54.62 Now $57.48 +5.24% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers